Welcome to our dedicated page for International Flavors&Fragranc news (Ticker: IFF), a resource for investors and traders seeking the latest updates and insights on International Flavors&Fragranc stock.
International Flavors & Fragrances Inc. reports developments across flavors, fragrances, food ingredients, health and biosciences for customers in food, beverage, personal care, home care, pet health and related markets. News frequently covers ingredient innovation, application labs and natural-extraction capabilities, including vanilla work in Madagascar and LMR Naturals in perfumery, cosmetics and flavors.
Company updates also address probiotics and bioscience products such as HOWARU Pet and PureStrong, nutrition claims tied to soy protein, quarterly earnings releases, dividends, and other capital or financial disclosures.
IFF (NYSE: IFF) has launched ScentChat™, an AI-powered instant messaging application designed to revolutionize fragrance creation through real-time consumer feedback. The app integrates with popular messaging platforms like WhatsApp and Facebook Messenger, enabling direct communication between consumers and fragrance creators.
Using advanced semantic AI and Natural Language Processing (NLP), ScentChat™ analyzes consumer feedback and generates instant insight reports that help perfumers make informed decisions about ingredients. The tool addresses traditional barriers in consumer research by offering a cost-effective, accessible, and scalable solution for gathering authentic sensory feedback.
The application represents a significant advancement in applying generative AI to perfumery, combining human experience with technology to streamline the fragrance creation process. It creates a collaborative environment between consumers and creators while making innovation more efficient and impactful.
IFF (NYSE:IFF) has announced its schedule for upcoming investor events in February 2025. The company will release its fourth quarter and full year 2024 earnings results after market close on February 18, 2025. A live webcast with management to discuss results and outlook will follow on February 19, 2025, at 9:00 a.m. ET.
Additionally, IFF management will present at the Consumer Analyst Group of New York (CAGNY) conference on February 20, 2025, at 1:00 PM ET. Both events will be accessible through webcasts on the company's investor relations website at ir.iff.com, with replay options available for those unable to attend live.
IFF (NYSE:IFF) has launched Enviva® DUO, a new direct-fed microbial (DFM) solution for poultry production. The product features a blend of two non-spore forming bacterial strains designed to support beneficial gut bacteria growth and promote optimal bird performance through waterline application.
The solution targets specific houses or farms through direct dosing, ensuring challenged birds receive microbiome-boosting benefits even during decreased feed intake. Scientific research validates Enviva® DUO's ability to restore bird microbiome and stabilize intestinal environment, while its stable formulation ensures uniform distribution without settling in water systems.
The product is currently available in the U.S., India, and Pakistan, with planned expansion to other markets pending regulatory approvals.
IFF Pharma Solutions has been awarded the 2024 Pharmaceutical Technology Excellence Award in the Brand Leadership category for its 'Timing is Everything' campaign. The campaign showcases IFF's new controlled release platform for oral drug delivery, implementing a three-pronged approach including social media teasers, video content, and a microsite.
The platform features key products including METHOCEL™, ETHOCEL™, and POLYOX™, focusing on controlled release polymers in pharmaceutical formulations. The campaign creates a comprehensive thought leadership platform providing educational resources such as white papers, webinars, and articles about controlled release of active ingredients.
The Pharmaceutical Technology Excellence Awards, powered by GlobalData's business intelligence, recognizes significant achievements and innovations in the pharmaceutical industry. The award acknowledges the campaign's strategic marketing tactics, creativity, and leadership in building an integrated thought leadership platform.
IFF (NYSE: IFF) has launched the China Scent Exploration Program, a consumer learning initiative aimed at creating unique fragrances for the Chinese market. This program leverages IFF's long-standing regional expertise, which began in 1981, and combines artificial intelligence with deep cultural insights.
According to Ana Paula Mendonça, President of Scent at IFF, the Chinese fragrance market offers significant opportunities. The program targets a market that includes fine fragrance ($2.15 billion), beauty and personal care ($77.35 billion), and home care ($18 billion).
The program is structured around four strategic pillars:
- Historical and cultural imprint: Analyzes traditional fragrance ingredients for modern use.
- Sensorial influences: Researches cultural and botanical references to develop authentic scent profiles.
- Consumer insights: Surveys 10,000 people across various cities and generations, monitoring social media trends.
- Artificial intelligence: Translates insights into precise fragrance creation guidelines.
Arnaud Montet, VP of Global Human & Consumer Insights, stated that this large-scale research enables targeted fragrance development, reducing time and costs.
The initiative addresses key market challenges, such as evolving consumer preferences and the need for culturally authentic fragrances, enhancing IFF's ability to guide strategic decisions and create tailored scents for the Chinese market.
IFF announced significant changes to its Board of Directors, effective through 2025. Kevin O'Byrne, current board member and Centrica plc chair, will become Board Chair at the 2025 Annual Shareholder Meeting, succeeding Roger W. Ferguson, Jr. who will not seek reelection after 14 years of service.
Three new directors - Cynthia Jamison, Dr. Mehmood Khan, and Vincent Intrieri - will join effective January 1, 2025. Intrieri's appointment comes at Icahn Capital LP's request, replacing Gary Hu. Additionally, Christina Gold and John Davidson will not seek reelection in 2025, resulting in a ten-member board structure.
IFF Pharma Solutions has launched AnswerCenter, a new web-based customer experience platform designed to enhance user experience and provide comprehensive support. The platform features an intuitive interface allowing customers to browse products by market, technology, or segment, with advanced filtering options for excipients and ingredients across pharmaceuticals, biologics, dietary supplements, and other sectors.
The platform provides access to detailed technical information, regulatory guidelines, and documentation related to product brands, quality, technical data sheets, supply chain, and regulatory support. AnswerCenter represents a key component of IFF's digital transformation strategy, aiming to streamline customer access to information while maintaining personal customer relationships.
IFF has announced the appointment of Michael DeVeau as Executive Vice President and Chief Financial Officer, effective January 1, 2025. DeVeau, currently Senior Vice President of Corporate Finance and Investor Relations, will succeed Glenn Richter, who will retire at the end of 2024.
DeVeau brings 15 years of experience at IFF, having served in multiple senior finance leadership roles including Divisional CFO of Scent and Chief Strategy Officer. In his current role, he oversees corporate and divisional financial planning and analysis, corporate strategy, and investor relations. Prior to IFF, he held positions at PepsiCo and started his career as an equity research analyst at Citigroup Investment Research.
IFF has launched TEXSTAR™, an innovative enzymatic solution designed to enhance texture in dairy and plant-based fermented products without added stabilizers. The enzyme converts sucrose into poly- and oligosaccharides during fermentation, reducing sugar content while delivering premium texture with greater smoothness and increased shine. TEXSTAR™ can reduce texturant-related Scope 3 greenhouse gas emissions by up to 90% due to lower usage rates and can serve as a partial milk protein replacer to reduce carbon footprint. The solution addresses consumer preferences, with 53% of US consumers eating yogurt as a snack and 42% seeking thick, spoonable consistency.
IFF reported strong Q3 2024 financial results with sales of $2.93 billion, up 4% from the previous year. On a comparable basis, currency neutral sales increased 9%, driven by growth across all segments. Adjusted operating EBITDA was $568 million, improving 16% year-over-year. The company achieved notable volume recovery in every division, with Health & Biosciences and Scent delivering double-digit performances. Based on strong performance, IFF increased its full-year 2024 guidance, now expecting sales between $11.3-11.4 billion and adjusted operating EBITDA at the high end of $2.1-2.17 billion range.